GSK has committed $50 million in upfront capital and near-term milestones to secure a license to two cancer research foundation models from Noetik. San Francisco-based Noetik has used spatial biology ...
GSK’s potential “functional cure” for hepatitis B drug has proven its worth in a pair of hotly anticipated phase 3 studies, setting up the pharma for a push to the FDA. The British drugmaker had been ...
If you are wondering whether GSK shares still offer value at around £18.86, you are not alone. The stock has been attracting fresh attention from investors asking the same question. Over the past year ...
SAN FRANCISCO--(BUSINESS WIRE)--Noetik, an AI-native biotech company pioneering self-supervised machine learning and high-throughput spatial data to develop next-generation cancer therapeutics, ...
A new Reuters report, based on data from healthcare research firm 3 Axis Advisors, names Pfizer (PFE) and GSK (GSK) among the leading drugmakers seeking to hike U.S. prices of as many as 360 branded ...
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. GSK’s treatment for chronic hepatitis B delivered a positive result in two late-stage trials and could provide ...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced positive results from two pivotal Phase 3 studies, B-Well 1 and B-Well 2, evaluating the safety and efficacy of bepirovirsen, an ...
In a move that could impact vaccine-makers like Merck & Co. Inc. (NYSE: MRK), GSK plc (NYSE: GSK), the U.S. government has decided to massively reduce the number of vaccines it recommends for every ...
Drugmakers are reportedly preparing to raise U.S. prices on at least 350 branded medicines in 2026, including vaccines for COVID-19, RSV, and shingles, as well as major cancer therapies, despite ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results